
Apixan2.5 mg
Unimed Unihealth MFG. Ltd.
Established / FDA-Approved Uses Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF): Apixaban is indicated to reduce the risk of stroke and systemic embolism in adult…
Apixaban is sometimes used off-label for other thromboembolic conditions (e.g., in certain patients with left ventricular thrombus) at the discretion of the treating physician; such use is not FDA-approved and should follow specialist advice.
| Indication | Recommended Dose |
|---|---|
| Stroke/systemic embolism prevention in non-valvular atrial fibrillation | 5 mg orally twice daily. Reduce to 2.5 mg twice daily if the patient meets at least 2 of: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. |
| Treatment of acute DVT/PE | 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily. |
| Reduction of recurrent DVT/PE (after ≥6 months of initial treatment) | 2.5 mg orally twice daily. |
| VTE prophylaxis after hip replacement surgery | 2.5 mg orally twice daily, starting 12–24 hours after surgery, for 35 days. |
| VTE prophylaxis after knee replacement surgery | 2.5 mg orally twice daily, starting 12–24 hours after surgery, for 12 days. |
Apixaban dosing in pediatric patients is weight-based and given after at least 5 days of initial parenteral anticoagulation; the treating physician determines the exact regimen based on body weight bands. Apixaban is not recommended in infants weighing less than 2.6 kg, as it has not been studied in this population.
No dose adjustment is required for DVT/PE treatment or prophylaxis based on renal function alone, including patients on hemodialysis. For NVAF, dose reduction applies only when the serum creatinine criterion above is met. Use in pediatric patients with significant renal impairment is not recommended.
No dose adjustment is needed in mild hepatic impairment (Child-Pugh A). Apixaban should be used with caution in moderate impairment (Child-Pugh B) and is not recommended in severe hepatic impairment (Child-Pugh C) due to limited clinical data.
The missed dose should be taken as soon as remembered on the same day, and dosing continued twice daily as before. Doses should not be doubled to make up for a missed dose.
The most common adverse reactions are related to bleeding, and their frequency depends on the indication and dose. These include:
Note: Apixaban is not recommended in patients with mechanical prosthetic heart valves, as safety and efficacy have not been established in this population; this is a use-limitation based on lack of studied benefit/safety rather than a classical absolute contraindication, but such use should be avoided.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.